Nasdaq Listing via Reverse Merger and Strategic Value

Caldera Therapeutics has decided to merge with Synlogic (SYBX), a Nasdaq-listed company, to quickly acquire a listing. Synlogic, after failing in a Phase 3 clinical trial for phenylketonuria (PKU) in February 2024, was left with only one full-time employee. However, Caldera utilized it as a listing vehicle, significantly reducing regulatory hurdles and time costs compared to a traditional IPO. In this merger, Synlogic was valued at $18 million, and Caldera at $500 million. After the merger, the combined entity will be renamed Caldera Therapeutics (CALD) and begin trading. This is considered a sophisticated financial strategy to avoid extreme market volatility while immediately securing flexible access to capital in the public market.

$278 Million PIPE Financing and Financial Stability

In conjunction with the reverse merger agreement, Caldera successfully completed a $278 million private investment in public equity (PIPE) financing, establishing a strong capital base. Bain Capital Life Sciences, TCGX, and Atlas Venture, leading global venture capital firms in the healthcare investment ecosystem, participated extensively in this large-scale financing. This provides Caldera with a financial runway to conduct research and development stably until 2029 without additional funding. Unlike many late-stage biotech companies struggling with funding due to prolonged high interest rates, securing long-term funding at the Phase 2 stage demonstrates the value of its pipeline and the company's viability.

Clinical Advantages of CLD-423, a Bispecific Antibody Targeting IL-23p19 and TL1A Simultaneously

Caldera's core competency is CLD-423 (Qyuns' development name: QX030N), a bispecific antibody candidate licensed from Qyuns Therapeutics (2509.HK) in April 2025 for a total of $555 million (including a $10 million upfront payment). Targeting patients with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), this molecule overcomes the limitations of existing single-target antibodies by simultaneously inhibiting IL-23p19, a key factor in inflammatory responses, and TL1A, which mediates tissue fibrosis and barrier damage. By controlling both inflammatory pathways, which have shown excellent efficacy with AbbVie's (ABBV) Skyrizi and Merck's (MRK) tulisokibart, it is considered an innovative game-changer that maximizes the synergistic effects of combination therapy and therapeutic remission rates.

Roadmap for Accelerating Global Clinical Trials and Market Leadership

With the global inflammatory bowel disease (IBD) therapeutics market reaching approximately $24 billion to $30 billion, Caldera is implementing a precise global clinical strategy to outpace its competitors. CLD-423 has successfully completed a Phase 1 clinical trial in healthy subjects, demonstrating good tolerability, approximately 80% subcutaneous (SC) bioavailability, and the potential for maintenance dosing every 8 to 12 weeks. The company plans to initiate a global, multi-center, placebo-controlled Phase 2b clinical trial for ulcerative colitis and simultaneously initiate a Phase 2 clinical trial for Crohn's disease in collaboration with its Chinese partner early next year. This is a strategic move to secure proof-of-concept data in patients faster than competing bispecific antibody pipelines, such as Boehringer Ingelheim's SIM0709, licensed from Simcere (2096.HK), and Xencor (XNCR), which has a total contract value of $1.2 billion.